Author:
Travis William D.,Dacic Sanja,Wistuba Ignacio,Sholl Lynette,Adusumilli Prasad,Bubendorf Lukas,Bunn Paul,Cascone Tina,Chaft Jamie,Chen Gang,Chou Teh-Ying,Cooper Wendy,Erasmus Jeremy J.,Ferreira Carlos Gil,Goo Jin-Mo,Heymach John,Hirsch Fred R.,Horinouchi Hidehito,Kerr Keith,Kris Mark,Jain Deepali,Kim Young T.,Lopez-Rios Fernando,Lu Shun,Mitsudomi Tetsuya,Moreira Andre,Motoi Noriko,Nicholson Andrew G.,Oliveira Ricardo,Papotti Mauro,Pastorino Ugo,Paz-Ares Luis,Pelosi Giuseppe,Poleri Claudia,Provencio Mariano,Roden Anja C.,Scagliotti Giorgio,Swisher Stephen G.,Thunnissen Erik,Tsao Ming S.,Vansteenkiste Johan,Weder Walter,Yatabe Yasushi
Funder
Genentech
Bayer HealthCare
Bristol-Myers Squibb
AstraZeneca
Medimmune
Pfizer
Merck
Roche
MSD
MD Anderson Cancer Center
Boehringer Ingelheim
MedImmune
Spectrum
EMD Serono
Takeda
Sanofi US
BMS
Chugai
Lilly
Ono Pharmaceuticals
Astellas
Genomic Health
Free To Breathe
Regeneron
National Cancer Institute
Lung Cancer Research Foundation
IBM
Thermo Fisher
AbbVie
Ono Pharmaceutical
Ethicon
Medtronic
Astra Zeneca
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference118 articles.
1. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement;Huvos;Arch Pathol Lab Med,1977
2. Osteosarcoma chemotherapy effect: a prognostic factor;Raymond;Semin Diagn Pathol,1987
3. Histopathologic features of prognostic significance in high-grade osteosarcoma;Chui;Arch Pathol Lab Med,2016
4. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer;Ali;Breast Cancer Res BCR,2016
5. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy;Peintinger;Mod Pathol,2015